VitaLonga

Clinical trial · Supplements / medicine · 15 Nov 2026

In 160 adolescents with obesity, weekly tirzepatide for 72 weeks lowered BMI more than placebo

Source: JAMA

What the research found

A phase 3 randomized double-blind trial was published online on 15 November 2026. It ran at 31 centers in Canada, the Czech Republic, Israel, Italy, Poland, and the United States. Adolescents aged 12 to younger than 18, with obesity or with overweight plus a related complication, were assigned 2 to 1 to weekly tirzepatide (raised to 5, 10, or 15 mg as tolerated) or placebo for 72 weeks, plus a lifestyle program. Of 160 participants, 109 received tirzepatide and 51 received placebo. Mean age was 14.6 (standard deviation 1.6). 99 participants (61.9 percent) were female. Mean body weight was 109.7 kg and mean BMI was 38.6. At week 72, BMI fell 18.5 percent with tirzepatide and rose 0.5 percent with placebo (difference -19.0 percentage points, 95 percent CI -23.9 to -14.1, p<0.001). A BMI drop of at least 5 percent occurred in 79.6 percent versus 28.5 percent (risk difference 51.2 percentage points, 95 percent CI 36.3 to 66.1, p<0.001). All 10 key secondary outcomes favored tirzepatide. The most common adverse events were gastrointestinal and mostly mild or moderate. The abstract does not give discontinuation counts. Registry NCT06075667. This trial tested tirzepatide in adolescents. It is not a dosing guide. DOI 10.1001/jama.2026.23420. Not medical advice.

Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.

Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read the original at JAMA

More supplements / medicine news